It is the major aim of the ICEPHA Graduate Program Membrane-associated Drug Targets in Personalized Cancer Medicine to improve future outcomes for people with cancer. In order to achieve this goal, the members to of the program take advantage of the synergy achieved through their combined expertise in the basic and clinical sciences.
The following key activities provide a general framework of the research in our consortium:
Validation of novel drug targets for personalized anti-tumor therapy
Identification of molecular markers as reliable predictors of treatment response
Establishment of new drugs for innovative treatment regimes
Optimization of the transfer of resources, technologies and expertise from academia to healthcare research and development of clinical trials in pharmaceutical industry